Sandström B
Gynecol Invest. 1978;9(4):195-204. doi: 10.1159/000300984.
In 101 hypertensive gravidae the selective beta-blocking agent metoprolol alone or in combination with hydralazine has been used. The effects of the mother and fetus have been compared with those of 97 hypertensive gravidae treated with hydralazine. In both groups a small dose of a thiazide was added. Perinatal mortality was lower in the metoprolol group (2.0%) than in the hydralazine group (8.0%). The rate of fetal growth retardations also was lower when using metoprolol (11.7 and 16.3% respectively). No abnormal effects of the beta-blocker was noticed on the fetus.
在101例妊娠高血压患者中，单独使用选择性β受体阻滞剂美托洛尔或与肼屈嗪联合使用。将母亲和胎儿的情况与97例接受肼屈嗪治疗的妊娠高血压患者进行了比较。两组均加用小剂量噻嗪类药物。美托洛尔组的围产期死亡率（2.0%）低于肼屈嗪组（8.0%）。使用美托洛尔时胎儿生长受限率也较低（分别为11.7%和16.3%）。未发现β受体阻滞剂对胎儿有异常影响。
